Needham analyst Michael Matson maintained a Hold rating on Resmed Inc (RMD) today. The company’s shares closed last Monday at $131.63.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 5.4% and a 59.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Boston Scientific Corp, and Cardiovascular Systems.
Currently, the analyst consensus on Resmed Inc is a Moderate Buy with an average price target of $100.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $141.25 and a one-year low of $90.64. Currently, Resmed Inc has an average volume of 506.5K.
Based on the recent corporate insider activity of 161 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry.
